Savient Pharmaceuticals to Present at the Bank of America Merrill Lynch 2011 Health Care Conference

Wed Apr 27, 2011 4:06pm EDT

* Reuters is not responsible for the content in this press release.

Savient Pharmaceuticals to Present at the Bank of America Merrill Lynch 2011 Health Care Conference

PR Newswire

EAST BRUNSWICK, N.J., April 27, 2011 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that John H. Johnson, Chief Executive Officer of Savient will present at the Bank of America Merrill Lynch 2011 Health Care Conference on Thursday, May 12, 2011, at 9:50 a.m. Pacific Time.  The conference will be held at Encore at the Wynn Las Vegas.

A live webcast of the presentation can be accessed through the investor relations section of the Savient website at www.savient.com.  Following the live presentation, a replay of the webcast will be available on the Company's website for 30 days.

ABOUT SAVIENT PHARMACEUTICALS, INC.

Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA® (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy.  Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University ("Duke") and Mountain View Pharmaceuticals, Inc. ("MVP").  Duke developed the recombinant uricase enzyme and MVP developed the PEGylation technology used in the manufacture of KRYSTEXXA.  MVP and Duke have been granted U.S. and foreign patents disclosing and claiming the licensed technology and, in addition, Savient owns or co-owns U.S. and foreign patents and patent applications, which collectively form a broad portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA.  Savient also manufactures and supplies Oxandrin® (oxandrolone tablets, USP) CIII in the U.S.  For more information, please visit the Company's website at www.savient.com.

SVNT - G

SOURCE Savient Pharmaceuticals, Inc.

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.